← Back to Search

Radiation Therapy

SBRT for Metastatic Disease

N/A

Waitlist Available

Led By Steve Burton, MD

Research Sponsored by Steven Burton

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 years

Awards & highlights

Study Summary

This trial will test whether a type of radiation called stereotactic body radiation (SRS) can be used to target cancer cells in patients with a limited number of cancer metastases.

Eligible Conditions

Recurrent Oligometastatic Disease

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Adverse Events Related to Treatment

Secondary outcome measures

Analysis of patterns of failure post-SRS/SBRT

Local control of metastatic sites

Overall survival (OS)

+2 more

Side effects data

From 2020 Phase 1 & 2 trial • 30 Patients • NCT01120639

67%

Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, death

50%

Headache

50%

Alopecia

17%

Seizure

17%

Nervous system disorders -Other, necrosis

17%

Syncope

17%

Nervous system disorders-Other, altered mental state

17%

Fatigue

100%

80%

60%

40%

20%

Study treatment Arm

Stereotactic Radiosurgery (25 Gray x 5 Fractions)+Temozolomide

Stereotactic Radiosurgery (40 Gray x 5 Fractions)+Temozolomide

Stereotactic Radiosurgery (30 Gray x 5 Fractions)+Temozolomide

Stereotactic Radiosurgery (35 Gray x 5 Fractions)+Temozolomide

Trial Design

1Treatment groups

Experimental Treatment

Group I: SBRTExperimental Treatment1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Stereotactic Radiosurgery (SRS)

2012

Completed Phase 2

~240

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Steven BurtonLead Sponsor

3 Previous Clinical Trials

50 Total Patients Enrolled

Steve Burton, MDPrincipal InvestigatorUniversity of Pittsburgh

1 Previous Clinical Trials

20 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies available for participants in this research?

"Information posted on clinicaltrials.gov indicates that this particular trial is not enrolling any more participants, since the last update was made in April 2021. However, there are currently 1032 different studies actively seeking patients for enrollment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Radiosurgery for Patients Recurrent Oligometastatic Disease

Steven Burton 2011. "Radiosurgery for Patients Recurrent Oligometastatic Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01345552.